Authors: Preisler, HD Venugopal, P Gregory, SA Hsu, WT Loew, J Adler, S Gezer, S Creech, S Galvez, A Slivnick, D Andric, T Larson, RA Jajeh, A

Citation: Hd. Preisler et al., Poor prognosis acute myelogenous leukemia: 1 - response to treatment with high dose cytarabine/mitoxantrone/ethyol @ (Amifostine), LEUK RES, 24(8), 2000, pp. 671-680

Authors: Raza, A Qawi, H Lisak, L Andric, T Dar, S Andrews, C Venugopal, P Gezer, S Gregory, S Loew, J Robin, E Rifkin, S Hsu, WT Huang, RW

Citation: A. Raza et al., Patients with myelodysplastic syndromes benefit from palliative therapy with amifostine, pentoxifylline, and ciprofloxacin with or without dexamethasone, BLOOD, 95(5), 2000, pp. 1580-1587

Authors: Reza, S Dar, S Andric, T Qawi, H Mundle, S Shetty, V Venugopal, P Ali, I Lisak, L Raza, A

Citation: S. Reza et al., Biologic characteristics of 164 patients with myelodysplastic syndromes, LEUK LYMPH, 33(3-4), 1999, pp. 281-287

Authors: Dar, S Mundle, S Andric, T Qawi, H Shetty, V Reza, S Mativi, BY Allampallam, K Ali, A Venugopal, P Gezer, S Broady-Robinson, L Cartlidge, J Showel, M Hussaini, S Ragasa, D Ali, I Chaudhry, A Waggoner, S Lisak, L Huang, RW Raza, A

Citation: S. Dar et al., Biological characteristics of myelodysplastic syndrome patients who demonstrated high versus no intramedullary apoptosis, EUR J HAEMA, 62(2), 1999, pp. 90-94